Johnson & Johnson (JNJ) – Major News
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 15c; Raises Outlook
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 18c; raises forecast
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 18c; Raises Outlook
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 11c, Revenues Misses; Guides EPS Above Views
-
Johnson & Johnson (JNJ) Acquires Abiomed (ABMD) for $380/sh or $16.6B, Plus CVR Worth Up to $35/sh
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 3c, Revenues Beat; Maintains Outlook
-
Johnson & Johnson (JNJ) Announces $5B Share Buyback
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; Maintains Operational Guidance at Midpoint, Cuts on Reported Basis
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 6c, Updates FY Guidance
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 1c
-
Johnson & Johnson (JNJ) to separate the Company's Consumer Health business
-
Johnson & Johnson (JNJ) to Split Into Two Public Companies, CEO Tells WSJ
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 22c, Updates FY Guidance
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 25c, Updates Guidance
-
U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death
-
Johnson & Johnson (JNJ) Single-Shot COVID-19 Vaccine Granted U.S. FDA Emergency Use Authorization
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 4c, Offers FY21 Guidance
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 22c, Raises FY Guidance
-
Johnson & Johnson (JNJ) to Acquire Momenta Pharmaceuticals Inc. (MNTA) for $52.50/Share
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 19c, Offers FY Guidance
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 31c; Lowers FY20 Guidance, Raises Dividend
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Offers FY20 Guidance
-
Johnson & Johnson (JNJ) Says 15 New Tests from Same Bottle of Baby Powder Previously Tested by FDA Find No Asbestos
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 11c
-
Johnson & Johnson (JNJ) Hit With $8B Punitive Damage Verdict Related to Male Breast Growth Linked to RISPERDAL
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 12c, Offers FY Guidance
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 6c
-
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4 Billion
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c, Offers FY Guidance
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 2c, Updates FY Guidance
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 3c, FY Guidance Misses Views
-
St. Louis Jury Returns $4.69 Billion Verdict Against J&J (JNJ) in First Trial Linking Baby Powder, Asbestos and Ovarian Cancer
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 5c
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c, FY Guidance Tops Views
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 10c; Raises Outlook
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 3c, Raises FY Guidance
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 6c; Guides Slightly Higher
-
Johnson & Johnson (JNJ) to Acquire Actelion (ALIOY) For $30B; to Spin-Off New R&D Company
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides Modestly Below the Street
-
Actelion and Johnson & Johnson (JNJ) enter exclusive talks
-
Sanofi (SNY) in Talks to Acquire Actelion (ALIOY) as Johnson & Johnson (JNJ) Bows Out
-
Actelion Confirms Johnson & Johnson (JNJ) Takeover Approach
-
Johnson & Johnson (JNJ) Approaches Actelion About a Takeover
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 3c; Boosts FY16 Outlook
-
Abbott (ABT) to Sell Abbott Medical Optics to Johnson & Johnson (JNJ) in $4.33B Deal
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 6c; Boosts FY16 Outlook
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 2c; Updates FY16 Outlook
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 4c; Boosts FY15 EPS Outlook
Back to JNJ Stock Lookup